Focused on building reliable datasets, financial models, and research tools for value-minded investors. Committed to turning complex data into practical guidance for value-investing and long-term wealth.
Dr. Charlie Tian is the founder and CEO of GuruFocus.com, a leading global investment research platform established in 2004. With a Ph.D. in physics, Dr. Tian transitioned from science to finance, applying a data-driven, disciplined approach to value investing.
Pharma AidsDHA:PHARMAID -2.55%73 FCF Margin % is 6.91% as of Mar. 2026, which is 7% above its 10-year median of 6.46. GuruFocus rates DHA:PHARMAID with a GF Score™ of 73/100 and a GF Value™ of BDT758.56 (Modestly Undervalued). The stock has 3 warning signs investors should review. Among 817 Medical Devices & Instruments companies, Pharma Aids ranks better than 54.1% on this metric.
FCF Margin % is calculated as Free Cash Flow divided by its Revenue. Pharma Aids's Free Cash Flow for the
three
months ended in Mar. 2026 was BDT8.5 Mil. Pharma Aids's Revenue for the
three
months ended in Mar. 2026 was BDT123.3 Mil. Therefore, Pharma Aids's FCF Margin % for the quarter that ended in Mar. 2026 was 6.91%.
The historical rank and industry rank for Pharma Aids's FCF Margin % or its related term are showing as below:
DHA:PHARMAID'
s FCF Margin % Range Over the Past 10 Years
Min: -7.05 Med: 6.46 Max: 13.24
Current: 1.24
During the past 13 years, the highest FCF Margin % of Pharma Aids was 13.24%. The lowest was -7.05%. And the median was 6.46%.
DHA:PHARMAID's FCF Margin % is ranked better than 54.1% of 817
companies
in the Medical Devices & Instruments industry
Industry Median: -0.54
vs DHA:PHARMAID: 1.24
Pharma Aids FCF Margin % Related Terms
Pharma Aids FCF Margin % Historical Data
* Premium members only.
The historical data trend for Pharma Aids's FCF Margin % can be seen below:
* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD. * For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.
DHA:PHARMAID vs ISRG, BDX, MDLN: FCF Margin % Comparison
For the Medical Instruments & Supplies subindustry, Pharma Aids's FCF Margin %, along with its competitors' market caps and FCF Margin % data, can be viewed below:
* Competitive companies are chosen from companies within the same industry, with headquarter located in same country, with closest market capitalization; x-axis shows the market cap, and y-axis shows the term value; the bigger the dot, the larger the market cap. Note that "N/A" values will not show up in the chart.
Pharma Aids FCF Margin % vs Medical Devices & Instruments Industry
For the Medical Devices & Instruments industry and Healthcare sector, Pharma Aids's FCF Margin % distribution charts can be found below:
* The bar in red indicates where Pharma Aids's FCF Margin % falls into.
* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD. * For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.
Pharma Aids (DHA:PHARMAID) has a FCF Margin % of 6.91% as of Mar. 2026. Free cash flow margin is the ratio of total free cash flow to net sales. View historical data on Pharma Aids and its competitors. This is near median its historical median of 6.46. According to the industry distribution chart, Pharma Aids ranks #375 out of 817 companies in the Medical Devices & Instruments industry, placing it in the top 45.9%.
Is Pharma Aids' FCF Margin % too high?
Pharma Aids' current FCF Margin % of 6.91% is near median its 10-year median of 6.46. Based on the distribution chart, Pharma Aids ranks #375 out of 817 companies in the Medical Devices & Instruments industry, which is above the industry midpoint. Overall, Pharma Aids has a GF Score™ of 73/100 and is considered Modestly Undervalued, reflecting its overall financial health beyond just this single metric.
How does Pharma Aids' FCF Margin % compare to ISRG and BDX?
According to the Medical Devices & Instruments industry distribution chart, Pharma Aids ranks #375 out of 817 companies for FCF Margin %. This puts Pharma Aids in the upper half of its industry. See the competitive comparison table and distribution chart on this page for a detailed peer-by-peer breakdown.
What is a good FCF Margin % for a Medical Devices & Instruments company?
A good FCF Margin % depends on the Medical Devices & Instruments industry context. However, FCF Margin % should not be evaluated in isolation — investors should consider it alongside profitability, growth, and financial strength metrics. Use the industry distribution chart on this page to see where any company falls relative to its peers.
What does a high FCF Margin % mean?
A high FCF Margin % can signal that a stock is expensive relative to its fundamentals. Free cash flow margin is the ratio of total free cash flow to net sales. View historical data on Pharma Aids and its competitors. Pharma Aids's current FCF Margin % is 6.91%, which is near median its own 10-year median of 6.46. However, context matters — high-growth companies often justify higher valuations. Always evaluate alongside other metrics like GF Score™ and GF Value™.
Is Pharma Aids stock overvalued right now?
Based on GuruFocus' analysis, Pharma Aids (DHA:PHARMAID) is currently considered Modestly Undervalued. The stock's GF Value™ is BDT758.56, compared to a current price of BDT644.70 — trading 15% below its estimated fair value. The current FCF Margin % is 6.91%, which is near median its 10-year median of 6.46. Pharma Aids' overall GF Score™ is 73/100 with 3 warning signs to review. Investors should evaluate multiple metrics — including profitability, growth, and financial strength — before making a decision.
How is FCF Margin % calculated?
FCF Margin % is calculated from a company's financial statements. For Pharma Aids (DHA:PHARMAID), the current FCF Margin % is 6.91% as of Mar. 2026. GuruFocus calculates this using data sourced from SEC filings and annual reports. See the calculation section and 30-year financial data on this page for the full breakdown.
Is Pharma Aids (DHA:PHARMAID) Overvalued in 2026?
Based on GuruFocus' analysis, Pharma Aids stock appears to be undervalued.
The current stock price of BDT644.70 is trading 15% below its estimated GF Value™ of BDT758.56.
GuruFocus considers Pharma Aids to be Modestly Undervalued.
Key valuation signals for DHA:PHARMAID:
FCF Margin %: 6.91% (near median its 10-year median of 6.46)
GF Value™: BDT758.56 vs. price of BDT644.70 (15% below fair value)
No single metric tells the full story. See the DHA:PHARMAID stock analysis page for a complete view including 30-year financials, guru trades, and insider activity.
Pharma Aids Ltd is a Bangladesh-based company engaged in the manufacturing of neutral glass ampoules, USP Type-I. Ampoules are used by pharmaceutical companies for filling liquid injections. The company produces different sizes of ampoules from 1ml to 25ml, in Clear and Amber color, and in Amber color, and of both Open Mouth (Form B and C) and Close Mouth (Form D, Din and Marzocchi type).
73GF Score
Get the complete analysis for DHA:PHARMAID
FCF Margin % is just one metric. See GF Value™, 30-year financials, guru trades, warning signs, and more.
Quick Browse
Personalize
Premium Gurus 
Create New Portfolio
DHA:PHARMAID has been successfully added to your 
